Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: erickerickson who wrote (48026)	12/10/2018 5:36:14 PM
From: surfsupdude	7 Recommendations Recommended By erippetoe idahoranch1 LLTD patlawche11 rodneyh07 and 2 more members Read Replies (2) \| Respond to of 63284

If this landed Friday, it explains the drop we saw mixed in with market selling. The fact that we bounced back in a tough market is a very good sign IMHO. It does a lot to explain the dialogue with FDA and they've had sufficient time to remediate these issues.

To: erickerickson who wrote (48026)	12/10/2018 6:38:47 PM
From: JJINV	2 Recommendations Recommended By LLTD sysiphus Read Replies (1) \| Respond to of 63284

It would seem as though the information was leaked, IMO, and thus the drop over the last weeks.. Was not 132 results related, but a factor in QC/Manuf/Facility... which given this was over 3 months ago now should have been adequatly resolved.. with a go forward measure of some new blood in the ranks to show/ensure moving forward is adhered to according to plan.